92 related articles for article (PubMed ID: 16103074)
1. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.
Delaval B; Létard S; Lelièvre H; Chevrier V; Daviet L; Dubreuil P; Birnbaum D
Cancer Res; 2005 Aug; 65(16):7231-40. PubMed ID: 16103074
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative disorders: the centrosome connection.
Delaval B; Lelièvre H; Birnbaum D
Leukemia; 2005 Oct; 19(10):1739-44. PubMed ID: 16107884
[TBL] [Abstract][Full Text] [Related]
3. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome.
Lelièvre H; Chevrier V; Tassin AM; Birnbaum D
Mol Cancer; 2008 Apr; 7():30. PubMed ID: 18412956
[TBL] [Abstract][Full Text] [Related]
5. FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice.
Guasch G; Delaval B; Arnoulet C; Xie MJ; Xerri L; Sainty D; Birnbaum D; Pébusque MJ
Blood; 2004 Jan; 103(1):309-12. PubMed ID: 12969958
[TBL] [Abstract][Full Text] [Related]
6. Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
Lee JY; Hong WJ; Majeti R; Stearns T
PLoS One; 2014; 9(3):e92641. PubMed ID: 24658090
[TBL] [Abstract][Full Text] [Related]
7. Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders.
Bochtler T; Kirsch M; Maier B; Bachmann J; Klingmüller U; Anderhub S; Ho AD; Krämer A
Leukemia; 2012 Apr; 26(4):728-35. PubMed ID: 22015771
[TBL] [Abstract][Full Text] [Related]
8. The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.
Jin Y; Zhen Y; Haugsten EM; Wiedlocha A
Cell Signal; 2011 Nov; 23(11):1758-66. PubMed ID: 21745565
[TBL] [Abstract][Full Text] [Related]
9. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Chen J; Deangelo DJ; Kutok JL; Williams IR; Lee BH; Wadleigh M; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Galinsky I; Huntly B; Cohen PS; Meyer T; Fabbro D; Roesel J; Banerji L; Griffin JD; Xiao S; Fletcher JA; Stone RM; Gilliland DG
Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14479-84. PubMed ID: 15448205
[TBL] [Abstract][Full Text] [Related]
10. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.
Murati A; Arnoulet C; Lafage-Pochitaloff M; Adélaide J; Derré M; Slama B; Delaval B; Popovici C; Vey N; Xerri L; Mozziconacci MJ; Boulat O; Sainty D; Birnbaum D; Chaffanet M
Int J Oncol; 2005 Jun; 26(6):1485-92. PubMed ID: 15870860
[TBL] [Abstract][Full Text] [Related]
11. Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase.
Kouhara H; Kurebayashi S; Hashimoto K; Kasayama S; Koga M; Kishimoto T; Sato B
Oncogene; 1995 Jun; 10(12):2315-22. PubMed ID: 7784079
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells.
Feng S; Wang F; Matsubara A; Kan M; McKeehan WL
Cancer Res; 1997 Dec; 57(23):5369-78. PubMed ID: 9393762
[TBL] [Abstract][Full Text] [Related]
13. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.
Xiao S; Nalabolu SR; Aster JC; Ma J; Abruzzo L; Jaffe ES; Stone R; Weissman SM; Hudson TJ; Fletcher JA
Nat Genet; 1998 Jan; 18(1):84-7. PubMed ID: 9425908
[TBL] [Abstract][Full Text] [Related]
14. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).
Guasch G; Mack GJ; Popovici C; Dastugue N; Birnbaum D; Rattner JB; Pébusque MJ
Blood; 2000 Mar; 95(5):1788-96. PubMed ID: 10688839
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Grand EK; Grand FH; Chase AJ; Ross FM; Corcoran MM; Oscier DG; Cross NC
Genes Chromosomes Cancer; 2004 May; 40(1):78-83. PubMed ID: 15034873
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase fusion genes in chronic myeloproliferative diseases.
Cross NC; Reiter A
Leukemia; 2002 Jul; 16(7):1207-12. PubMed ID: 12094244
[TBL] [Abstract][Full Text] [Related]
17. [FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12].
Pébusque MJ; Chaffanet M; Popovici C; Birnbaum D
Bull Cancer; 2000 Dec; 87(12):887-94. PubMed ID: 11174118
[TBL] [Abstract][Full Text] [Related]
18. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
19. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1.
Popovici C; Zhang B; Grégoire MJ; Jonveaux P; Lafage-Pochitaloff M; Birnbaum D; Pébusque MJ
Blood; 1999 Feb; 93(4):1381-9. PubMed ID: 9949182
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 1 phosphotyrosine 766: molecular target for prevention of progression of prostate tumors to malignancy.
Wang F; McKeehan K; Yu C; McKeehan WL
Cancer Res; 2002 Mar; 62(6):1898-903. PubMed ID: 11912171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
